Grufity logoGrufity logo

Vaxart Inc Stock Research

VXRT

0.79USD+0.03(+3.95%)Delayed

Market Summary

USD0.79+0.03
Delayed
3.95%

VXRT Stock Price

VXRT RSI Chart

VXRT Valuation

Market Cap

101.4M

Price/Earnings (Trailing)

-0.97

Price/Sales (Trailing)

637.62

EV/EBITDA

-0.51

Price/Free Cashflow

-1.15

VXRT Price/Sales (Trailing)

VXRT Profitability

EBT Margin

-65745.28%

Return on Equity

-85.53%

Return on Assets

-59.67%

Free Cashflow Yield

-86.95%

VXRT Fundamentals

VXRT Revenue

Revenue (TTM)

159.0K

Revenue Y/Y

-100%

Revenue Q/Q

-100%

VXRT Earnings

Earnings (TTM)

-104.6M

Earnings Y/Y

-66.69%

Earnings Q/Q

0.41%

Price Action

52 Week Range

0.735.43
(Low)(High)

Last 7 days

-6.8%

Last 30 days

-16.5%

Last 90 days

-31.5%

Trailing 12 Months

-83.0%

VXRT Financial Health

Current Ratio

5.54

VXRT Investor Care

Shares Dilution (1Y)

3.51%

Peers (Alternatives to Vaxart)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
125.3B
26.3B
-2.75% 3.76%
19.12
4.76
1.32% 11.18%
99.6B
27.3B
-8.96% 41.01%
21.68
3.65
-0.09% -26.23%
58.4B
19.3B
-12.76% 1.00%
6.99
3.03
4.29% -31.47%
38.3B
10.2B
-9.67% 32.94%
12.57
3.76
-7.36% 95.80%
MID-CAP
9.1B
1.5B
-9.09% 3.35%
58.87
6.11
31.34% 72.43%
3.2B
108.5M
-21.10% -19.55%
-9.78
29.38
122.90% -12.19%
2.5B
60.9M
-18.47% -36.46%
-8.76
41.55
17.51% 22.00%
2.1B
107.9M
22.95% 67.45%
-4.29
19.27
54.84% 17.36%
SMALL-CAP
1.2B
112.0M
-14.86% -46.41%
-4.63
11.04
-70.76% -603.77%
1.1B
7.0M
-22.18% 24.65%
-7.11
158.97
131.81% -45.39%
541.9M
96.3M
-12.99% -82.24%
-1.92
5.63
72.44% -32.79%
513.7M
2.0B
-39.67% -92.01%
-0.78
0.26
72.89% 62.27%
355.3M
111.3M
-30.55% -58.78%
-1.85
3.19
0.54% -7.86%
101.4M
159.0K
-16.47% -82.96%
-0.97
637.62
-86.46% -64.56%
25.1M
-
94.03% -77.12%
-0.31
3.21
0.51% -185.61%

Financials for Vaxart

Income Statement (Last 12 Months)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue-32.7%107,000159,000359,000471,000892,000
Operating Expenses6.4%114,694,000107,823,00095,848,00082,488,00073,644,000
  S&GA Expenses2.4%29,386,00028,693,00026,775,00022,604,00021,890,000
  R&D Expenses6.5%81,054,00076,125,00066,068,00056,879,00048,749,000
EBITDA-12.7%-99,422,000-88,233,000-75,132,000-66,155,000-
EBITDA Margin-154.4%-625-245-159-74.16-
Earnings Before Taxes-3.0%-107,691,000-104,535,000-92,804,000-79,475,000-70,363,000
EBT Margin-154.3%-657-258-168-78.88-
Interest Expenses-0.00----
Net Income-3.0%-107,758,000-104,604,000-92,878,000-79,564,000-70,470,000
Net Income Margin-154.3%-657-258-168-79.00-
Free Cahsflow-1.2%-88,156,000-87,104,000-74,241,000-64,989,000-
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets-12.2%154175181200221
  Current Assets-17.4%99.00120138154169
    Cash Equivalents-9.4%46.0051.0091.00123144
  Net PPE26.9%16.0012.009.008.007.00
  Goodwill0%5.005.005.005.005.00
Liabilities-18.4%43.0053.0038.0034.0034.00
  Current Liabilities-17.6%18.0022.0016.0011.0011.00
Shareholder's Equity-9.6%111122143166188
  Retained Earnings-7.9%-327-303-273-244-219
  Additional Paid-In Capital2.8%438426417411407
Accumulated Depreciation23.0%3.002.002.001.00-
Shares Outstanding4.6%134128126126126
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations-16.4%-94.78-81.44-81.09-68.35-59.83
  Share Based Compensation3.7%14.0013.0012.0011.009.00
Cashflow From Investing54.0%-20.41-44.39-17.73-24.81-49.10
Cashflow From Financing86.3%17.009.0025.0059.00126

Risks for VXRT

What is the probability of a big loss on VXRT?

100%


Probability that Vaxart stock will be more than 20% underwater in next one year

100%


Probability that Vaxart stock will be more than 30% underwater in next one year.

100%


Probability that Vaxart stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does VXRT drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Vaxart was unfortunately bought at previous high price.

Drawdowns

Returns for VXRT

Cumulative Returns on VXRT

-34.5%


5-Year Cumulative Returns

-19.5%


3-Year Cumulative Returns

What are the long-term rolling returns for VXRT?

FIve years rolling returns for Vaxart.

Annualized Returns

Which funds bought or sold VXRT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
reduced
-0.04
-17,342
13,658
-%
2023-02-28
Voya Investment Management LLC
unchanged
-
-56,479
44,521
-%
2023-02-24
NATIXIS
sold off
-100
-42,000
-
-%
2023-02-21
MACQUARIE GROUP LTD
sold off
-100
-20,000
-
-%
2023-02-16
GHP Investment Advisors, Inc.
unchanged
-
154
154
-%
2023-02-16
HARBOUR INVESTMENTS, INC.
unchanged
-
-3,550
1,450
-%
2023-02-15
JANE STREET GROUP, LLC
added
389
454,952
847,952
-%
2023-02-15
CI Private Wealth, LLC
new
-
17,608
17,608
-%
2023-02-15
Metropolitan Life Insurance Co/NY
added
7.11
-8,255
7,745
-%
2023-02-15
Steward Partners Investment Advisory, LLC
reduced
-20.00
-2,463
1,537
-%

1–10 of 45

Latest Funds Activity

Are funds buying VXRT calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own VXRT
No. of Funds

Vaxart News

Yahoo Finance

Vaxart, Inc. (NASDAQ:VXRT) Q4 2022 Earnings Call Transcript.

Yahoo Finance,
34 hours ago

Simply Wall St

The Business Journals

The Dwinnex

Armenian Reporter

Stocks Register

InvestorsObserver

Schedule 13G FIlings of Vaxart

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
vanguard group inc
5.35%
7,019,507
SC 13G
Feb 01, 2023
blackrock inc.
6.7%
8,858,225
SC 13G/A
Jan 10, 2023
state street corp
1.83%
2,398,264
SC 13G/A
Mar 10, 2022
state street corp
10.39%
13,072,021
SC 13G/A
Feb 11, 2022
state street corp
8.91%
11,187,642
SC 13G/A
Feb 07, 2022
blackrock inc.
6.7%
8,452,420
SC 13G
Feb 11, 2021
state street corp
8.63%
9,444,967
SC 13G
Jun 09, 2020
armistice capital, llc
19.99%
16,785,583
SC 13D/A
May 27, 2020
armistice capital, llc
11.3%
8,400,000
SC 13D/A
May 18, 2020
armistice capital, llc
14.0%
10,350,000
SC 13D/A

VXRT Fair Value

Vaxart fair value in different scenarios

The table shows the Fair Value estimates for Vaxart for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

0.23

-70.89%

0.23

-70.89%

0.23

-70.89%

0.23

-70.89%

0.23

-70.89%
Current Inflation

0.23

-70.89%

0.23

-70.89%

0.23

-70.89%

0.23

-70.89%

0.23

-70.89%
Very High Inflation

0.23

-70.89%

0.23

-70.89%

0.23

-70.89%

0.23

-70.89%

0.23

-70.89%

Historical Vaxart Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Vaxart

View All Filings
Date Filed Form Type Document
Mar 16, 2023
8-K
Current Report
Mar 15, 2023
10-K
Annual Report
Feb 09, 2023
SC 13G
Major Ownership Report
Feb 01, 2023
SC 13G/A
Major Ownership Report
Jan 10, 2023
SC 13G/A
Major Ownership Report
Dec 30, 2022
4
Insider Trading
Dec 30, 2022
3
Insider Trading
Dec 28, 2022
4
Insider Trading
Dec 19, 2022
8-K
Current Report

Latest Insider Trading transactions for VXRT

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-12-28
Watson W. Mark
bought
15,140
0.757
20,000
-
2022-12-16
Lee Phillip E
acquired
-
-
206,250
chief financial officer
2022-08-25
HERON ELAINE J
acquired
-
-
14,750
-
2022-08-24
Yedid Robert A.
gifted
-
-
-26,240
-
2022-08-19
Yedid Robert A.
acquired
24,774
0.944146
26,240
-
2022-08-04
Wheadon David E.
acquired
-
-
7,375
-
2022-08-04
Yedid Robert A.
acquired
-
-
7,375
-
2022-08-04
Watson W. Mark
acquired
-
-
14,750
-
2022-08-04
Cherrington Julie M
acquired
-
-
6,217
-
2022-08-04
Davis Todd C
acquired
-
-
7,375
-

1–10 of 50

Andrei Floroiu
110
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.

VXRT Income Statement

2022-12-31
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Revenue from Contract with Customer, Including Assessed Tax$ 107$ 892
Operating expenses:  
Research and development81,05448,749
General and administrative29,38621,890
Impairment of intangible assets4,2543,005
Total operating expenses114,69473,644
Operating loss(114,587)(72,752)
Other income (expense):  
Interest income1,24781
Non-cash interest expense related to sale of future royalties(1,305)(1,480)
Gain on remeasurement of future royalty liability6,9603,789
Foreign exchange loss, net(6)(1)
Loss before income taxes(107,691)(70,363)
Provision for income taxes67107
Net loss$ (107,758)$ (70,470)
Net loss per share attributable to common stockholders, basic and diluted (in dollars per share)$ (0.84)$ (0.58)
Shares used to compute net loss per share, basic and diluted (in shares)127,683,813121,453,723
Comprehensive loss:  
Net loss$ (107,758)$ (70,470)
Unrealized loss on available-for-sale investments, net of tax(225)(74)
Comprehensive loss(107,983)(70,544)
Customer Service Contracts [Member]  
Revenue from Contract with Customer, Including Assessed Tax013
Non Cash Royalty Revenue [Member]  
Revenue from Contract with Customer, Including Assessed Tax$ 107$ 879

VXRT Balance Sheet

2022-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Current assets:  
Cash, cash equivalents and restricted cash$ 46,013$ 143,745
Short-term investments49,70422,742
Accounts receivable2071
Prepaid expenses and other current assets3,7142,609
Total current assets99,451169,167
Long-term investments016,210
Property and equipment, net15,5856,601
Right-of-use assets, net25,71513,168
Intangible assets, net5,02010,624
Goodwill4,5084,508
Other long-term assets3,568890
Total assets153,847221,168
Current liabilities:  
Accounts payable5,5143,872
Deferred grant revenue2,0000
Other accrued current liabilities8,0845,064
Current portion of operating lease liability2,2281,011
Current portion of liability related to sale of future royalties95836
Total current liabilities17,92110,783
Operating lease liability, net of current portion19,47711,997
Liability related to sale of future royalties, net of current portion5,62110,686
Other long-term liabilities231171
Total liabilities43,25033,637
Commitments and contingencies (Note 9)
Stockholders’ equity:  
Preferred Stock: $0.0001 par value; 5,000,000 shares authorized; none issued and outstanding as of December 31, 2022 or 202100
Common Stock: $0.0001 par value; 250,000,000 and 150,000,000 shares authorized as of December 31, 2022 and 2021, respectively; 134,199,429 and 125,594,393 shares issued and outstanding as of December 31, 2022 and 2021, respectively1313
Additional paid-in capital437,992406,943
Accumulated deficit(327,109)(219,351)
Accumulated other comprehensive loss(299)(74)
Total stockholders’ equity110,597187,531
Total liabilities and stockholders’ equity$ 153,847$ 221,168